Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 09, 2020 06:00 ET | Source: Qu Biologics, Inc.

Qu Biologics Completes $8M Financing

VANCOUVER, British Columbia, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel...
August 24, 2020 06:00 ET | Source: Qu Biologics, Inc.

Qu Biologics is pleased to announce the appointment of Karn Manhas to Qu’s Board of Directors

VANCOUVER, British Columbia, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies...
August 18, 2020 14:35 ET | Source: Qu Biologics, Inc.

Qu Biologics Initiates Phase 2 Study to Assess Activation of Anti-cancer Immune Response in Colon Cancer

VANCOUVER, British Columbia, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies...
April 06, 2020 06:00 ET | Source: Qu Biologics, Inc.

Qu Biologics publishes landmark studies showing cells of the innate immune system can be directed to target organ sites to prevent and clear pathology and infection

VANCOUVER, British Columbia, April 06, 2020 (GLOBE NEWSWIRE) -- Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of...
December 18, 2019 17:35 ET | Source: Qu Biologics, Inc.

Qu Biologics Completes Enrollment in First Stage of Phase 2 Clinical Trial in Moderate to Severe Crohn’s Disease

VANCOUVER, British Columbia, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel immunotherapy platform...
July 23, 2019 06:00 ET | Source: Qu Biologics, Inc.

Qu Biologics publishes potentially paradigm-shifting results of their first randomized-placebo controlled trial for the treatment of Crohn’s disease

VANCOUVER, British Columbia, July 23, 2019 (GLOBE NEWSWIRE) -- Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of...
November 13, 2018 06:00 ET | Source: Qu Biologics, Inc.

First stage of Qu Biologics’ clinical trial assessing mucosal healing for novel immunotherapy for Crohn’s disease reaches 50% enrolment

VANCOUVER, British Columbia, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of...
November 05, 2018 09:00 ET | Source: Qu Biologics, Inc.

Qu Biologics’ Site Specific Immunomodulators Enhance Adoptive T cell Therapies in Solid Tumours

VANCOUVER, British Columbia, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies...
October 01, 2018 07:00 ET | Source: Qu Biologics, Inc.

Researchers discover that activating innate immunity in the gastrointestinal tract reduces disease pathology in ulcerative colitis

VANCOUVER, British Columbia, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of...
July 25, 2018 12:53 ET | Source: Qu Biologics

Qu Biologics enrolls the first patient in new Phase 2 Crohn’s Disease clinical trial

VANCOUVER, British Columbia, July 25, 2018 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right